Cargando…

Acute toxicity and quality of life in prostate cancer patients treated with definitive hypofractionated pelvic radiation therapy: a single-center report

BACKGROUND: The objective was to report acute toxicity and quality of life in prostate cancer patients treated with definitive hypofractionated pelvic radiation therapy. MATERIALS AND METHODS: Patients were designated candidates for hypofractionated pelvic radiation therapy if biopsy or imaging stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mandel, Isidora King, Díaz, Felipe Kovacic, García, Lorena Vargas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Via Medica 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547407/ https://www.ncbi.nlm.nih.gov/pubmed/37795391 http://dx.doi.org/10.5603/RPOR.a2023.0043

Ejemplares similares

Toxicity and Outcomes of Moderately Hypofractionated Radiation for Prostate Cancer With Seminal Vesicle Involvement
por: Acklin-Wehnert, Scarlett, et al.
Publicado: (2023)

Effect of Large Prostate Volume on Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy in Patients With Prostate Cancer
por: Natesan, Divya, et al.
Publicado: (2021)

Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer
por: Wang, Wei Gang, et al.
Publicado: (2017)

Acute toxicity profile in prostate cancer with conventional and hypofractionated treatment
por: Viani, Gustavo Arruda, et al.
Publicado: (2013)

Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer
por: Pinitpatcharalert, Attapol, et al.
Publicado: (2019)

Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy
por: McDonald, Andrew M, et al.
Publicado: (2014)

The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States
por: Moore, Assaf, et al.
Publicado: (2019)

SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer: Toxicity and quality of life assessment
por: Rucinska, Monika, et al.
Publicado: (2016)

Normal tissue toxicity after small field hypofractionated stereotactic body radiation
por: Milano, Michael T, et al.
Publicado: (2008)

Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: A Randomized Clinical Trial
por: Mariados, Neil F., et al.
Publicado: (2023)

Hypofractionated Postmastectomy Radiation Therapy
por: Sayan, Mutlay, et al.
Publicado: (2020)

Hypofractionated radiotherapy for prostate cancer
por: Hegemann, Nina-Sophie, et al.
Publicado: (2014)

Moderate hypofractionation for prostate cancer
por: Arcangeli, Stefano, et al.
Publicado: (2017)

Moderate hypofractionation for prostate cancer
por: Lee, W. Robert, et al.
Publicado: (2018)

The role of hypofractionated radiotherapy for the definitive treatment of localized prostate cancer: early results of a randomized trial
por: Alexidis, Petros, et al.
Publicado: (2019)

Extreme Hypofractionation with SBRT in Localized Prostate Cancer
por: Gómez-Aparicio, Maria Antonia, et al.
Publicado: (2021)

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
por: Ju, Andrew W, et al.
Publicado: (2013)

Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial
por: Beaudry, M.M., et al.
Publicado: (2023)

Hypofractionation of radiation dose to the prostate does not necessarily imply a greater risk of acute radiation proctitis
por: Ferini, Gianluca, et al.
Publicado: (2023)

Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003
por: Laughlin, Brady S., et al.
Publicado: (2022)

Adaptive radiation therapy strategies in the treatment of prostate cancer patients using hypofractionated VMAT
por: Siciarz, Pawel, et al.
Publicado: (2021)

Review of Hypofractionated Radiotherapy for Prostate Cancer
por: Spyropoulou, Despina, et al.
Publicado: (2012)

The Role of Hypofractionated Radiotherapy in Prostate Cancer
por: Benjamin, Linus C., et al.
Publicado: (2017)

Hypofractionation trials and radiobiology of prostate cancer
por: Gulliford, Sarah, et al.
Publicado: (2017)

Image Guided Hypofractionated Radiotherapy by Helical Tomotherapy for Prostate Carcinoma: Toxicity and Impact on Nadir PSA
por: Barra, Salvina, et al.
Publicado: (2014)

Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis
por: Tamihardja, Jörg, et al.
Publicado: (2020)

Does Intensity Modulated Radiation Therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?
por: Guckenberger, Matthias, et al.
Publicado: (2008)

Prostate-specific antigen kinetics in hypofractionated radiation therapy alone for intermediate- and high-risk localized prostate cancer
por: Lee, Tae Hoon, et al.
Publicado: (2023)

Long-term clinical outcomes of salvage pelvic radiation therapy for oligo-recurrent pelvic lymph nodes after definitive external-beam radiation therapy for non-metastatic prostate cancer
por: Sato, Genki Edward, et al.
Publicado: (2020)

Hypofractionated Radiotherapy in African Cancer Centers
por: Swanson, William, et al.
Publicado: (2021)

Hypofractionated helical intensity-modulated radiotherapy of the prostate bed after prostatectomy with or without the pelvic lymph nodes - the PRIAMOS trial
por: Krause, Sonja, et al.
Publicado: (2012)

Time to definitive fixation of pelvic and acetabular fractures
por: Devaney, Giles L., et al.
Publicado: (2020)

Intermediate-risk prostate cancer patients treated with androgen deprivation therapy and a hypofractionated radiation regimen with or without image guided radiotherapy
por: Valeriani, Maurizio, et al.
Publicado: (2013)

The Role of Hypofractionated Radiation Therapy with Photons, Protons, and Heavy Ions for Treating Extracranial Lesions
por: Laine, Aaron Michael, et al.
Publicado: (2016)

Low Incidence of Fatigue after Hypofractionated Stereotactic Body Radiation Therapy for Localized Prostate Cancer
por: Dash, Chiranjeev, et al.
Publicado: (2012)

Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial
por: Voong, K. Ranh, et al.
Publicado: (2017)

Assessment of non-inferiority with meta-analysis: example of hypofractionated radiation therapy in breast and prostate cancer
por: Trone, Jane-Chloé, et al.
Publicado: (2020)

Hypofractionated Radiation Therapy for Large Brain Metastases
por: Masucci, Giuseppina Laura
Publicado: (2018)

Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study
por: Jorgo, Kliton, et al.
Publicado: (2019)

Feasibility of Dose Escalating [(18)F]fluciclovine Positron Emission Tomography Positive Pelvic Lymph Nodes During Moderately Hypofractionated Radiation Therapy for High-Risk Prostate Cancer
por: McDonald, Andrew M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ho0hbh7fg8d2d9v45okvlmaqd4